| abstract |
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIPO I PCT omit VIII °nolo o1111 1111101 ow (10) International Publication Number WO 2018/134695 Al (51) International Patent Classification: CO7D 401/08 (2006.01) CO7D 295/185 (2006.01) CO7D 401/12 (2006.01) A61K 31/4747 (2006.01) C07D 491/10 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/IB2018/050103 (22) International Filing Date: 08 January 2018 (08.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/448,498 20 January 2017 (20.01.2017) US (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, New York, New York 10017 (US). (72) Inventors: BRODNEY, Michael Aaron; 100 Upland Avenue, Newton, Massachusetts 02461 (US). BUTLER, Christopher Ryan; 121 Spring Lane, Canton, Massachu- setts 02021 (US). MCALLISTER, Laura Ann; 428 Mass- achusetts Ave., Apt. 6, Arlington, Massachusetts 02474 (US). HELAL, Christopher John; 18 Elm Street, Mystic, Connecticut 06355 (US). O'NEIL, Steven Victor; 42 Ar- bor Crossing, East Lyme, Connecticut 06333 (US). VER- HOEST, Patrick Robert; 23 Calvin Road, Newton, Mass- achusetts 02460 (US). (74) Agent: WALDRON, Roy F.; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.17(i)) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) (54) Title: 1,1,1-TRIFLUOR0-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS O CF 3 (57) : The present invention provides, in part, compounds of Formula (I) and pharmaceutically acceptable salts thereof; © processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer. |